Abstract
The use of radionuclide labels allows to study the pharmacokinetics of monoclonal antibodies, to control the specificity of their targeting and to monitor the response to an antibody treatment with high accuracy. Selection of label depends on the processing of an antibody after binding to an antigen, and on the character of information to be derived from the study (distribution of antibody in the extracellular space, target occupancy or determination of sites of metabolism). This chapter provides protocols for labelling of antibodies with iodine-125 (suitable also for other radioisotopes of iodine) and with indium-111. Since radiolabelling might damage and reduce the immunoreactive fraction and/or affinity of an antibody, the methods for assessment of these characteristics of an antibody are provided for control.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
van Dongen GA et al (2007) Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist 12:1379–1389
Geissler F et al (1992) Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res 52:2907–2915
Kyriakos RJ et al (1992) The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 52:835–842
Mattes MJ et al (1994) Processing of antibody–radioisotope conjugates after binding to the surface of tumor cells. Cancer 73:787–793
Shih LB et al (1994) The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med 35:899–908
Tolmachev V, Orlova A, Lundqvist H (2003) Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides. Curr Med Chem 10:2447–2460
DeNardo GL et al (2004) Radiometals as payloads for radioimmunotherapy for lymphoma. Clin Lymphoma 5(Suppl 1):S5–S10
Malmberg J et al (2011) Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody. Nucl Med Biol 38:1093–1102
Hunter WM, Greenwood FC (1962) Preparation of iodine-131 labelled human growth hormones of high specific activity. Nature 194:495–496
Wilbur DS (1992) Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling. Bioconjug Chem 3:433–470
Olafsen T et al (1996) Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: application to radiolabeling. Acta Oncol 35:297–301
Nikula TK et al (1995) Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity. Mol Immunol 32:865–872
Olafsen T et al (1995) Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: location of lysine residues and implications for radiolabeling. Nucl Med Biol 22:765–771
Lindmo T et al (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72:77–89
Koziorowski J, Henssen C, Weinreich R (1998) A new convenient route to radioiodinated N-succinimidyl 3- and 4-iodobenzoate, two reagents for iodination of proteins. Appl Radiat Isot 49:955–959
Björke H, Andersson K (2006) Automated, high-resolution cellular retention and uptake studies in vitro. Appl Radiat Isot 64:901–905
Björkelund H et al (2011) Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with 125I-EGF. PLoS One 6:e24739
Önell A, Andersson K (2005) Kinetic determinations of molecular interactions using Biacore–minimum data requirements for efficient experimental design. J Mol Recognit 18:307–317
Björkelund H, Gedda L, Andersson K (2011) Avoiding false negative results in specificity analysis of protein–protein interactions. J Mol Recognit 24:81–89
Wadas TJ, Anderson CJ (2006) Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64. Nat Protoc 1:3062–3068
Wållberg H et al (2010) Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-ZHER2:2395-Cys affibody molecule for targeting of HER2-expressing tumors. Mol Imaging Biol 12:54–62
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Tolmachev, V., Orlova, A., Andersson, K. (2014). Methods for Radiolabelling of Monoclonal Antibodies. In: Steinitz, M. (eds) Human Monoclonal Antibodies. Methods in Molecular Biology, vol 1060. Humana, Totowa, NJ. https://doi.org/10.1007/978-1-62703-586-6_16
Download citation
DOI: https://doi.org/10.1007/978-1-62703-586-6_16
Published:
Publisher Name: Humana, Totowa, NJ
Print ISBN: 978-1-62703-585-9
Online ISBN: 978-1-62703-586-6
eBook Packages: Springer Protocols